Tibotec was a pharmaceutical company with a focus on

research Research is creative and systematic work undertaken to increase the stock of knowledge. It involves the collection, organization, and analysis of evidence to increase understanding of a topic, characterized by a particular attentiveness to ...

and development of the treatment of infectious diseases such as

HIV/AIDS The HIV, human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. Without treatment, it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS). It is a Preventive healthcare, pr ...

and

hepatitis C Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection period, people often have mild or no symptoms. Early symptoms can include ...

. The company was founded in 1994 and then acquired by

Johnson & Johnson Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a c ...

and merged into its

Janssen Pharmaceuticals Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Ph ...

division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment. The name of the company is derived from the ''tetrahydro-imidazo ,5,1-jk1,4]-benzodiazepine-2(1H)-one and -thione'' (TIBO) compounds discovered at the Rega Institute for Medical Research (

Belgium Belgium, officially the Kingdom of Belgium, is a country in Northwestern Europe. Situated in a coastal lowland region known as the Low Countries, it is bordered by the Netherlands to the north, Germany to the east, Luxembourg to the southeas ...

History

In 1994,

Rudi Pauwels Rudi Pauwels (born 1960) is a Belgian Pharmacology, pharmacologist and Biotechnology, biotech entrepreneur. He was one of the first researchers in the field of HIV, and he played a key role in the fight against the HIV/AIDS, AIDS pandemic by ...

of the

Rega Institute for Medical Research The Rega Institute for Medical Research is a Belgian scientific establishment that is part of the Katholieke Universiteit Leuven, Catholic University of Leuven (Leuven) in central Belgium. The Rega Institute is an interfacultary biomedical resear ...

founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by

in April 2002, and was renamed Janssen Therapeutics in June 2011. Tibotec provided funding for

HIV treatment The human immunodeficiency viruses (HIV) are two species of '' Lentivirus'' (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the im ...

clinical trials at the

Infectious Diseases Institute The Infectious Diseases Institute (IDI), established within Makerere University, is a Ugandan not-for-profit organization which aims to strengthen health systems in Africa, with a strong emphasis on infectious diseases; through research and capac ...

Kampala Kampala (, ) is the Capital city, capital and largest city of Uganda. The city proper has a population of 1,875,834 (2024) and is divided into the five political divisions of Kampala Central Division, Kampala, Kawempe Division, Kawempe, Makindy ...

Uganda Uganda, officially the Republic of Uganda, is a landlocked country in East Africa. It is bordered to the east by Kenya, to the north by South Sudan, to the west by the Democratic Republic of the Congo, to the south-west by Rwanda, and to the ...

Drugs

Darunavir Darunavir (DRV), sold under the brand name Prezista among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It is often used with low doses of ritonavir ...

(TMC114, tradename Prezista), a protease inhibitor *

Etravirine Etravirine (ETR,), sold under the brand name Intelence is an antiretroviral medication used for the treatment of HIV. Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike age ...

(TMC125, tradename Intelence), a

non-nucleoside reverse transcriptase inhibitor Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replicatio ...

(NNRTI) *

Bedaquiline Bedaquiline, sold under the brand name Sirturo, is a medication used for the treatment of active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis along with other medications for tuberculosis. It is taken by mo ...

(TMC207/R207910, tradename Sirturo), an diarylquinoline anti-

tuberculosis Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is a contagious disease usually caused by ''Mycobacterium tuberculosis'' (MTB) bacteria. Tuberculosis generally affects the lungs, but it can al ...

drug *

Rilpivirine Rilpivirine, sold under the brand name Edurant among others, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency (pharma ...

(TMC278, tradename Edurant), an NNRTI *

Simeprevir Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include ...

(TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2. * Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

References

External links

Tibotec
{{J&J Pharmaceutical companies of Belgium Johnson & Johnson subsidiaries Pharmaceutical companies established in 1994 Defunct pharmaceutical companies 2002 mergers and acquisitions

History

Drugs

See also

References

External links